免疫检查点抑制剂在EGFR突变非小细胞肺癌中:系统性审查
Ilaria Attili1, Antonio Passaro1, Carla Corvaja1
1Division of Thoracic Oncology, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141 Milan, Italy.
Cancer treatment reviews
|July 23, 2023
概括
免疫检查点抑制剂 (ICI) 对EGFR突变非小细胞肺癌 (NSCLC) 的益处有限. 与抗血管生成药物和化疗相结合显示出有希望的结果,但需要进一步的试验.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 基因组学就是基因组学.
背景情况:
- 免疫检查点抑制剂 (ICI) 在患有表皮生长因子受体 (EGFR) 突变的非小细胞肺癌 (NSCLC) 患者中表现出有限的疗效.
- 目前正在探索组合ICI策略,以增强该患者亚组的免疫激活.
研究的目的:
- 根据最新的证据,系统地审查基于ICI的策略在EGFR突变NSCLC中的有效性.
- 评估各种ICI组合疗法在这种特定癌症类型中的潜力.
主要方法:
- 发表文献的系统审查.
- 对ICI单疗法,ICI加化学疗法,ICI与抗血管原剂和化学疗法联合疗法的疗效数据的分析.
主要成果:
- 在EGFR突变NSCLC中,ICI单疗和ICI加化学疗是无效的.
- 将ICI与抗血管原剂和化疗结合起来显示出有前途的结果.
- 针对瘤免疫微环境的替代ICI组合存在有限的数据.
结论:
- 目前的证据不支持在患有EGFR突变的NSCLC患者中使用ICI.
- 目前正在进行的临床试验旨在确定EGFR突变NSCLC的最佳时间和新的ICI组合.
关键词:
在Atezolizumab中使用.欧洲农业基金会 (EGFR) 是一个.ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI IC1 ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI IC1 IC1 IC1 IC1 IC1 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC1 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which免疫治疗是一种免疫疗法.在NSCLCLC中,我们可以看到NSCLCLC.佩姆布罗利兹马布的使用方法更多相关视频
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


